Many studies have shown the existence of functional interactions between central neurotransmitter systems and the hypothalamo-pituitary adrenal axis. Mineralocorticoid receptors (MR) and glucocorticoid receptors (GR) are regulated by multiple factors including glucocorticoids themselves. Neurotransmitters such as serotonin (5-hydroxytryptamine: 5-HT) can regulate brain corticosteroid receptors in a complex way. The present study examined the short-term (48 h) effects of parachlorophenylalanine (PCPA), a drug which specifically inhibits 5-HT synthesis, on corticosteroid receptor levels and on the expression of their respective messenger ribonucleic acids (mRNA) in the rat hippocampus, hypothalamus and brain stem. The study was performed in bilaterally adrenalectomized animals, in order to avoid potential drug-induced changes in plasma corticosterone levels, which could secondarily regulate MR and GR. Short-term inhibition of 5-HT synthesis by PCPA significantly increased the number of hippocampal MR-binding sites. PCPA treatment did not alter the number of GR-binding sites in the hippocampus, hypothalamus and brain stem. We observed no change in the affinities of GR and MR sites in all the structures studied. In PCPA-treated rats, restoration of control 5-HT levels by injection of its immediate precursor, 5-hydroxytryptophan (5-HTP) brings the number of hippocampal MR-binding sites back to control levels. It can therefore be concluded that the increase in number of MR-binding sites induced by acute PCPA treatment is dependent on the decrease in 5-HT levels. The increase in hippocampal MR binding sites was correlated with an induction of their messengers, suggesting that 5-HT modulates the synthesis of MR protein. Although PCPA did not modify the number of hippocampal GR-binding sites, a decrease in hippocampal GR mRNA expression was observed. This study shows that 5-HT inhibits hippocampal mineralocorticoid receptor synthesis and that this effect is not mediated by changes in corticosterone hormone secretion, and illustrates the existence of complex mechanisms for corticosteroid receptor regulation in the hippocampus.

Keywords:
Serotonin, Adrenal steroid receptors, Adrenalectomy, p-Chlorophenylalanine, 5-Hydroxytryptophan
1.
McEwen BS, de Kloet ER, Rostene W: Adrenal steroid receptors and actions in the nervous system. Physiol Rev 1986;66:1121–1188.
2.
Azmitia EC, Liao B, Chen Y-S: Increase of tryptophan hydroxylase enzyme protein by dexamethasone in adrenalectomized rat midbrain. J Neurosci 1993;13:5041–5055.
3.
Reul JMHM, de Kloet ER: Two receptor systems for corticosterone in rat brain: Microdistribution and differential occupation. Endocrinology 1985;117:2505–2511.
4.
van Eekelen JA, Jiang W, de Kloet ER, Bohn MC: Distribution of the mineralocorticoid and the glucocorticoid receptor mRNAs in the rat hippocampus. J Neurosci Res 1988;21:88–94.
5.
Reul JMHM, de Kloet ER: Anatomical resolution of two types of corticosterone receptor sites in rat brain with in vivo autoradiography and computerized image analysis. J Steroid Biochem 1986;24:269–272.
6.
Lowy MT: Corticosterone regulation of brain and lymphoid corticosteroid receptors. J Steroid Biochem Mol Biol 1991;39:147–154.
7.
Reul JMHM, van den Bosch FR, de Kloet ER: Differential response of type I and type II corticosteroid receptors to changes in plasma steroid level and circadian rhythmicity. Neuroendocrinology 1987;45:407–412.
8.
Spencer RL, Miller AH, Stein M, McEwen BS: Corticosterone regulation of type I and type II adrenal steroid receptors in brain, pituitary and immune tissue. Brain Res 1991;549:236–246.
9.
Fuxe K, Wikstrom AC, Okret S, Agnati LF, Harfstrand A, Yu ZY, Granholm L, Zoli M, Vale W, Gustafsson JA: Mapping of glucocorticoid receptor immunoreactive neurons in the rat tel- and diencephalon using a monoclonal antibody against rat liver glucocorticoid receptor. Endocrinology 1985;117:1803–1812.
10.
Harfstrand A, Fuxe K, Cintra A, Agnati LF, Zini I, Wikstrom AC, Okret S, Yu ZY, Goldstein M, Steinbusch H, Verhofstad A, Gustafsson JA: Glucocorticoid receptor immunoreactivity in monoaminergic neurons or rat brain. Proc Natl Acad Sci USA 1986;83:9779–9783.
11.
Seckl JR, Dickson KL, Fink G: Central 5,7-dihydroxytryptamine lesions decrease hippocampal glucocorticoid and mineralocorticoid receptor messenger ribonucleic acid expression. J Neuroendocrinol 1990;2:911–916.
12.
Siegel RA, Weidenfeld J, Chen M, Feldman S, Melamed E, Chowers I: Hippocampal cell nuclear binding of corticosterone following 5,7-dihydroxytryptamine. Mol Cell Endocrinol 1983;31:253–259.
13.
Seckl JR, Fink G: Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992;55:621–626.
14.
Mitchell JB, Rowe W, Boksa P, Meaney MJ: Serotonin regulates type II corticosteroid receptor binding in hippocampal cell cultures. J Neurosci 1990;10:1745–1752.
15.
van de Kar LD: Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Annu Rev Pharmacol Toxicol 1991;31:289–320.
16.
Novotney S, Lowy MT: Short-term and long-term effects of p-chloroamphetamine on hippocampal serotonin and corticosteroid receptor levels. Brain Res 1995;684:19–25.
17.
Yau JLW, Noble J, Seckl JR: Site-specific regulation of corticosteroid and serotonin receptor subtype gene expression in the rat hippocampus following 3,4-methylenedioxymethamphetamine: Role of corticosterone and serotonin. Neuroscience 1997;78:111–121.
18.
Hutson PH, Curzon G: Concurrent determination of effects of p-chloroamphetamine on central extracellular 5-hydroxytryptamine concentration and behavior. Br J Pharmacol 1989;96:801–806.
19.
Leonardi ET, Azmitia EC: MDMA (Ecstasy) inhibition of MAO type A and type B: Comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 1994;10:231–238.
20.
Reul JMHM, Pearce PT, Funder JW, Krozowski ZS: Type I and type II corticosteroid receptor gene expression in the rat: Effect of adrenalectomy and dexamethasone administration. Mol Endocrinol 1989;3:1674–1680.
21.
Hery M, Laplante E, Kordon C: Participation of serotonin in the phasic release of LH. I. Evidence from pharmacological experiments. Endocrinology 1976;99:496–503.
22.
Spencer RL, Young EA, Choo PH, McEwen BS: Adrenal steroid type I and type II receptor binding: Estimates of in vivo receptor number, occupancy, and activation with varying level of steroid. Brain Res 1990;514:37–48.
23.
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–251.
24.
Munson PJ, Rodbard D: LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980;107:220–239.
25.
Grino M, Guillaume V, Castanas E, Boudouresque F, Conte-Devolx B, Oliver C: Effect of passive immunization against corticotropin-releasing factor (CRF) on the post-adrenalectomy changes of CRF binding sites in the rat anterior pituitary gland. Neuroendocrinology 1987;45:492–497.
26.
Martin CE, Cake MH, Hartmann PE, Cook IF: Relationship between foetal corticosteroids, maternal progesterone and parturition in the rat. Acta Endocrinol 1997;84:167–176.
27.
Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
28.
Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM: Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science 1987;237:268–275.
29.
Miesfeld R, Rusconi S, Godowski PJ, Maler BA, Okret S, Wikström AC, Gustafsson JA, Yamamoto KR: Genetic complementation of glucocorticoid receptor deficiency by expression of cloned receptor cDNA. Cell 1986;46:389–399.
30.
Tannenbaum B, Rowe W, Sharma S, Diorio J, Steverman A, Walker M, Meaney MJ: Dynamic variations in plasma corticosteroid-binding globulin and basal HPA activity following acute stress in adult rats. J Neuroendocrinol 1997;9:163–168.
31.
Szafarczyk A, Ixart G, Malaval F, Nouguier-Soule J, Assenmacher I: Effects of lesions of the suprachiasmatic nuclei and of p-chlorophenylalanine on the circadian rhythms of adrenocorticotrophic hormone and corticosterone in the plasma, and on locomotor activity of rats. J Endocrinol 1979;83:1–16.
32.
Yau JLW, Kelly PAT, Sharkey J, Seckl JR: Chronic 3,4-methylenedioxymethamphetamine administration decreases glucocorticoid and mineralocorticoid receptor, but increases 5-hydroxytryptamine1c receptor gene expression in the rat hippocampus. Neuroscience 1994;61:31–40.
33.
Herman JP, Patel PD, Akil H, Watson SJ: Localization and regulation of glucocorticoid and mineralocorticoid receptor messenger RNAs in the hippocampal formation of the rat. Mol Endocrinol 1989;3:1886–1894.
34.
Bamberger CM, Schulte HM, Chrousos GP: Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996;17:245–261.
35.
Olsson T, Hakansson A, Seckl JR: Ketanserin selectively blocks acute stress-induced changes in NGFI-A and mineralocorticoid receptor gene expression in hippocampal neurons. Neuroscience 1996;76:441–448.
36.
Encio IJ, Detera-Wadleigh SD: The genomic structure of the human glucocorticoid receptor. J Biol Chem 1991;266:7182–7188.
37.
Lowy MT: Reserpine-induced decrease in type I and II corticosteroid receptors in neuronal and lymphoid tissues of adrenalectomized rats. Neuroendocrinology 1990;51:190–196.
38.
Azmitia EC, McNaughton N, Tsaltas L, Fillenz M, Gray JA: Interactions between hippocampal serotonin and the pituitary-adrenal axis in the septal driving of hippocampal theta-rhythm. Neuroendocrinology 1984;39:471–475.
39.
De Kloet ER: Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 1991;12:95–164.
40.
Evans RM, Arriza JL: A molecular framework for the actions of glucocorticoid hormones in the nervous system. Neuron 1989;2:1105–1112.
41.
van Steensel B, van Binnendijk EP, Hornsby CD, van der Voort HT, Krozowski ZS, de Kloet ER, van Driel R: Partial colocalization of glucocorticoid and mineralocorticoid receptors in discrete compartments in nuclei of rat hippocampus neurons. J Cell Sci 1996;109:787–792.
42.
Tsai MJ, O’Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451–486.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.